- Home
- COYA vs CNTB Comparison
COYA vs CNTB Comparison
Compare COYA & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COYA | CNTB |
|---|---|---|
| Founded | 2020 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.6M | 128.6M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | COYA | CNTB |
|---|---|---|
| Price | $4.00 | N/A |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | |
| Target Price | $15.80 | N/A |
| AVG Volume (30 Days) | 120.6K | N/A |
| Earning Date | 05-12-2026 | 04-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | $7,945,753.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1,050.79 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 123.57 | N/A |
| 52 Week Low | $3.71 | N/A |
| 52 Week High | $7.75 | N/A |
Technical Indicators
Market Signals| Indicator | COYA | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 37.61 | 53.00 |
| Support Level | $3.94 | $2.16 |
| Resistance Level | $5.16 | $3.23 |
| Average True Range (ATR) | 0.25 | 0.34 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 30.92 | 35.43 |
Price Performance
Historical ComparisonAbout COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
About CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.